Correction of Swedish language version of notice to extraordinary general meeting in Klaria Pharma Holding AB (publ)

Correction of Swedish language version of notice to extraordinary general meeting in Klaria Pharma Holding AB (publ)

Due to a typographical error, the Swedish version of the press release regarding the notice to the Extraordinary General Meeting, that was made public today on 3 December 2019, had incorrect numbering of the proposed items on the agenda. However, the correct numbering is stated in the English language version of the press release, and will be stated in the formal notice that will be published in the Official Swedish Gazette (Sw. Post- och Inrikes Tidningar) on Wednesday 4 December 2019. The Swedish language version of the notice to the extra ordinary general meeting on the company’s website has been updated with this correction and the correct numbering is as follows:

Proposed agenda

0.              Opening of the meeting

1.              Election of chairman of the meeting;

2.              Preparation and approval of the voting list;

3.              Approval of the agenda;

4.              Election of one (1) or two (2) persons who shall approve the minutes of the meeting;

5.              Determination of whether the meeting has been duly convened;

6.              Resolution on merger with Karessa Pharma Holding AB (publ)

(a)    approval of merger plan, and

(b)    issue of merger consideration.

7.              Closing of the meeting.

For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Scott Boyer, CSO Klaria Pharma Holding AB (publ)
scott.boyer@klaria.com
Tel: +46 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.